Assay Quantifies CMV Deoxyribonucleic Acid from Human Plasma
By LabMedica International staff writers Posted on 07 Jul 2014 |
A flexible, fully automated, random access molecular diagnostics system for the quantitative and qualitative analysis of molecular targets from clinical patient specimens has been developed.
The VERIS system developed by Beckman Coulter Diagnostics (Brea, CA, USA) integrates key steps in molecular diagnostics to streamline workflow and system management, while processing critical STAT samples and ensuring prompt delivery of results. By providing continuous access, one-step loading, and individual test reporting, VERIS helps medical laboratory professionals advance and optimize the molecular diagnostics lab, by providing the control and freedom to give the right answer at the right time—for patients and physicians.
The CMV assay is a polymerase chain reaction (PCR) assay designed for the quantitative determination of CMV deoxyribonucleic acid (DNA) from human plasma. When used in conjunction with clinical presentation and other laboratory findings, the CMV assay aids in monitoring CMV viral load.
Beckman Coulter Diagnostics obtained the CE marking for the VERIS MDx System and VERIS human Cytomegalovirus (CMV) assay: a key milestone in the expansion of Beckman Coulter’s presence in molecular diagnostics.
Beckman Coulter is committed to the ongoing development of assays to expand the VERIS infectious disease portfolio and plans to submit for CE marking on assays for Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV) in 2014.
Richard Creager, senior vice president, molecular diagnostics business unit, and CSO at Beckman Coulter Diagnostics, commented, “After extensive research and development, Beckman Coulter has applied its expertise in diagnostics with our in‐depth knowledge of workflow to bring molecular diagnostics to the clinical laboratory. We have spent tremendous effort on understanding the needs of molecular laboratory professionals to develop a system that simplifies molecular diagnostic testing, while delivering the results that patients and clinicians need.”
Related Links:
Beckman Coulter Diagnostics
The VERIS system developed by Beckman Coulter Diagnostics (Brea, CA, USA) integrates key steps in molecular diagnostics to streamline workflow and system management, while processing critical STAT samples and ensuring prompt delivery of results. By providing continuous access, one-step loading, and individual test reporting, VERIS helps medical laboratory professionals advance and optimize the molecular diagnostics lab, by providing the control and freedom to give the right answer at the right time—for patients and physicians.
The CMV assay is a polymerase chain reaction (PCR) assay designed for the quantitative determination of CMV deoxyribonucleic acid (DNA) from human plasma. When used in conjunction with clinical presentation and other laboratory findings, the CMV assay aids in monitoring CMV viral load.
Beckman Coulter Diagnostics obtained the CE marking for the VERIS MDx System and VERIS human Cytomegalovirus (CMV) assay: a key milestone in the expansion of Beckman Coulter’s presence in molecular diagnostics.
Beckman Coulter is committed to the ongoing development of assays to expand the VERIS infectious disease portfolio and plans to submit for CE marking on assays for Human Immunodeficiency Virus (HIV), Hepatitis C virus (HCV) and Hepatitis B virus (HBV) in 2014.
Richard Creager, senior vice president, molecular diagnostics business unit, and CSO at Beckman Coulter Diagnostics, commented, “After extensive research and development, Beckman Coulter has applied its expertise in diagnostics with our in‐depth knowledge of workflow to bring molecular diagnostics to the clinical laboratory. We have spent tremendous effort on understanding the needs of molecular laboratory professionals to develop a system that simplifies molecular diagnostic testing, while delivering the results that patients and clinicians need.”
Related Links:
Beckman Coulter Diagnostics
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia